Senvest Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Senvest Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-75,042	Closed	-$1.94M	–	63
2017 Q4	$1.94M	Sell	75,042 -239,587	-76%	-$4.82M	0.14%	50
2017 Q3	$4.64M	Buy	314,629 +258,329	+459%	+$3.75M	0.31%	47
2017 Q2	$785K	Buy	+56,300	New	+$830K	0.06%	57

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Senvest Management's CNCE Position: Q1 2018 in Review

Senvest Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2018, closing a stake of 75,042 shares — an estimated $1.94M sold.

Senvest Management first reported a position in CNCE in Q2 2017 and held it in 3 quarters. The position peaked at $4.64M in Q3 2017. 123 funds tracked by Wall St. Rank hold CNCE as of Q1 2018.

Senvest Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Senvest Management sold 75,042 Concert Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.94M.
Senvest Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
Senvest Management's Concert Pharmaceuticals, Inc. position peaked at $4.64M in Q3 2017.
123 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2018.

Based on Senvest Management's 13F filing for Q1 2018, filed 14 May 2018.